Memo Therapeutics is a biotechnology research company that engages in antibody discovery and immune repertoire analysis.
Memo Therapeutics has raised $22.0M in total funding. The most recent round was Series C. The last funding was announced in May 2024.
Memo Therapeutics's investors include Schroders Capital, Kurma Partners, Ysios Capital, Verve Ventures, redalpine.
Memo Therapeutics is headquartered in Schlieren, Switzerland.
Memo Therapeutics is a biotechnology research company that engages in antibody discovery and immune repertoire analysis.
Memo Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Memo Therapeutics — Funding & Investors." VCBacked, May 7, 2024, https://www.vcbacked.co/company/memo-therapeutics. Accessed September 30, 2026.
VCBacked. (2024). Memo Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/memo-therapeutics
{{cite web |title=Memo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/memo-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated